80TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2026 Sustained investment in development and manufacturing infrastructure Modern drug development programs rely on increasingly sophisticated infrastructure. Facilities must accommodate specialized modalities, processes and emerging technologies. Analytical capabilities must support complex characterization and evolving regulatory expectations. Digital systems must enable visibility across development, manufacturing, and supply operations. Increasingly, advanced analytics, automation, and artificial intelligence are being integrated into these environments to help teams interpret complex data, anticipate operational constraints, and make faster development decisions. These capabilities rarely emerge in response to a single program. More often, they develop over time through sustained investment in facilities, technologies, and operational platforms. In practice, this kind of infrastructure allows development organizations to support programs as they evolve. Manufacturing processes may need to scale as clinical demand increases. New analytical approaches may be required as molecules become more complex. Clinical supply strategies may expand across regions as programs advance through later-stage trials. When the necessary capabilities already exist within the development environment, these transitions can occur without introducing delays. Organizations that maintain this long-term investment approach are better positioned to support emerging modalities and evolving and phased development strategies without waiting for capabilities to catch up to program needs. In that sense, infrastructure becomes more than physical capacity. It creates the operational readiness that allows development programs to move forward even as scientific and strategic conditions change. Coordination across development and supply Drug development has historically been organized around functional stages: research, development, manufacturing, and supply. Each stage brings specialized expertise and operational priorities. As development programs accelerate and complexity increases, the boundaries between these stages are becoming more interconnected. Formulation and analytical decisions can influence manufacturing feasibility. Manufacturing planning can affect clinical supply strategies earlier in the lifecycle. Clinical expansion into new regions can reshape supply considerations. Clinical development timelines can also influence CMC strategy earlier than in the past. As clinical programs accelerate, manufacturing readiness, formulation stability, and supply planning often need to progress in parallel with trial execution rather than sequentially. These interdependencies are becoming more visible earlier in development. Decisions about formulation, process design, or analytical methods may have implications for manufacturing scale-up or supply strategies months or years later. When those implications are understood early, teams can make adjustments before programs reach critical transition points. Greater coordination across these functions helps teams anticipate downstream implications earlier and make development decisions with a clearer view of their operational impact. When development, manufacturing, and supply teams operate with shared visibility into program objectives and constraints, programs are more likely to progress without disruption as they move through critical transitions between development, manufacturing, and supply. How development complexity is reshaping partner expectations As development complexity grows, biotech and biopharma companies are evaluating development partners through a broader operational lens. Scientific expertise and specialized technologies remain essential considerations. Increasingly, companies advancing new therapies are also looking closely at the conditions that support reliable execution across the full span of development to commercialization. Consistency and timeline certainty are important factors. Companies want confidence that work performed during development can translate into commercial-scale ready manufacturing processes and clinical supply without introducing unnecessary variability or delay. Scalability is another priority. Programs may expand across regions, production volumes, THERMO FISHER SCIENTIFIC
RkJQdWJsaXNoZXIy MjY2OTA4MA==